CA1180679A - Method of production of vitamin-d - Google Patents
Method of production of vitamin-dInfo
- Publication number
- CA1180679A CA1180679A CA000395862A CA395862A CA1180679A CA 1180679 A CA1180679 A CA 1180679A CA 000395862 A CA000395862 A CA 000395862A CA 395862 A CA395862 A CA 395862A CA 1180679 A CA1180679 A CA 1180679A
- Authority
- CA
- Canada
- Prior art keywords
- vitamin
- product
- product containing
- irradiating
- nanometers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 229940046008 vitamin d Drugs 0.000 title description 9
- XQFJZHAVTPYDIQ-BIADAZNZSA-N (1s)-3-[(z)-2-[(1r,3ar,7ar)-1-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-1,2,3,3a,6,7-hexahydroinden-4-yl]ethenyl]-4-methylcyclohex-3-en-1-ol Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)/C=C/[C@H](C)C(C)C)\C=C/C1=C(C)CC[C@H](O)C1 XQFJZHAVTPYDIQ-BIADAZNZSA-N 0.000 claims abstract description 19
- YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 claims abstract description 18
- YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000001678 irradiating effect Effects 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 6
- XQFJZHAVTPYDIQ-LETJEVNCSA-N (1s)-3-[(e)-2-[(1r,3ar,7ar)-1-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-1,2,3,3a,6,7-hexahydroinden-4-yl]ethenyl]-4-methylcyclohex-3-en-1-ol Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)/C=C/[C@H](C)C(C)C)\C=C\C1=C(C)CC[C@H](O)C1 XQFJZHAVTPYDIQ-LETJEVNCSA-N 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims description 22
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 14
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 11
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000007858 starting material Substances 0.000 claims description 10
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 8
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 8
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 8
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 8
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 7
- YUGCAAVRZWBXEQ-FMCTZRJNSA-N tachysterol 3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C\C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-FMCTZRJNSA-N 0.000 claims description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 6
- 229960002061 ergocalciferol Drugs 0.000 claims 6
- 235000001892 vitamin D2 Nutrition 0.000 claims 6
- 239000011653 vitamin D2 Substances 0.000 claims 6
- 235000005282 vitamin D3 Nutrition 0.000 claims 6
- 239000011647 vitamin D3 Substances 0.000 claims 6
- 229940021056 vitamin d3 Drugs 0.000 claims 6
- 239000000543 intermediate Substances 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 abstract description 8
- 229930003231 vitamin Natural products 0.000 abstract description 8
- 235000013343 vitamin Nutrition 0.000 abstract description 8
- 239000011782 vitamin Substances 0.000 abstract description 8
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 8
- BUNBVCKYYMRTNS-UHFFFAOYSA-N tachysterol Natural products C=1CCC2(C)C(C(C)CCC(C)C(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 BUNBVCKYYMRTNS-UHFFFAOYSA-N 0.000 abstract description 4
- 229930003316 Vitamin D Natural products 0.000 description 8
- 235000019166 vitamin D Nutrition 0.000 description 8
- 239000011710 vitamin D Substances 0.000 description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 238000006303 photolysis reaction Methods 0.000 description 6
- 230000015843 photosynthesis, light reaction Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 3
- DNVPQKQSNYMLRS-YAPGYIAOSA-N lumisterol Chemical compound C1[C@@H](O)CC[C@@]2(C)[C@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-YAPGYIAOSA-N 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001149 thermolysis Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034809 Product contamination Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 230000001749 antrachitic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
TITLE
METHOD OF PRODUCTION OF VITAMIN-D
I N V E N T O R S
Vincenzo Malatesta Clive Willis Peter A. Hackett ABSTRACT OF DISCLOSURE
A method of upgrading a product containing a minor proportion of pre-vitamin d2 or pre-vitamin d3 and a major proportion of tachysterol comprising irradiating the product with laser light in the -wavelength range 330-360 nanometers to obtain a product containing ap-proximately 95% pre-vitamin -D2 or pre-vitamin -D3, and heating this product to convert the pre-vitamin -D2 or pre-vitamin -D3 to vitamin -D2 or vitamin -D3.
METHOD OF PRODUCTION OF VITAMIN-D
I N V E N T O R S
Vincenzo Malatesta Clive Willis Peter A. Hackett ABSTRACT OF DISCLOSURE
A method of upgrading a product containing a minor proportion of pre-vitamin d2 or pre-vitamin d3 and a major proportion of tachysterol comprising irradiating the product with laser light in the -wavelength range 330-360 nanometers to obtain a product containing ap-proximately 95% pre-vitamin -D2 or pre-vitamin -D3, and heating this product to convert the pre-vitamin -D2 or pre-vitamin -D3 to vitamin -D2 or vitamin -D3.
Description
This invention relates to a method of production of vitamin-D and more particularly to laser photochemical conversion of 7-dehydro-cholesterol ~o vi~min -D3 and ergosterol to vitamin -D2 Vitamin D is not a single substance, but only 2 of 5 the lC or 11 sterols known to have antirachitic properties are of importance medically. These are activated ergosterol and 7-dehydro-cholesterol. The D substances are activated sterols complex substances often closely associated with fats in plants and animals. Cholesterol is an important sterol which is present in the skin; activation`
10 of cholesterol by ultraviolet light changes the compound and produces vitamin D.
The complex photochemistry of 7-dehydro-cholesterol (7-DHC) and ergosterol ~E) is now moderately well understood due to the studies of E. Havinga and his co-workers. See especially the following papers: Loevoet A.L.; Verloop A.; and Havinga E., Red. Trav.
Chim., Pays-Bas, 1955, 74,788 and Boosma F.; Jacobs H.J.C.; and Havinga E.; Vanclès Gen. ~., Tetrahedron Litt. 1975, 7,427.
The present commercial method of vitamin-D production involves a number of fractional crystallizations to isolate the required product. This method is described in French Patent No:
1,378,122, issued 1964 to K.R. Bhaurichter and F.M. Martin.
The use of photolysis with lasers or other light sources to achieve product separation is now well known. The use of photolysis in the production of vitamin-D is known but present methods have had the problem of the production of side products such as tachysterol, lumisterol and other isomers. These methods have required additional process steps such as fractional distillations to obtain the required separation percentages.
It is an object of the present invention to provide a method of producing vitamin-D that gives improved yields and reduced side product contamination.
This and other objects of the invention are achieved by a method involving photolysis at a selected wavelength.
In drawings which illustrate an embodiment of the 40 invention:
Figure 1 is a flow diagram of the process, and 67~
Figure 2 is a cross-sectio~al view of apparatus for carrying out the process.
Referring to figure 1~ the starting material, 7-dehydro-cholesterol (7-D~C) or ergosterol is irradiated with light in the wavelength range 245-260 mm. A low pressure mercury arc which functions at 254 nm. is most suitable for this. This photolysis may also be achieved by the use of an excimer laser ~KrF at 248 nm). Pre-vitamin-D3 or pre-vitamin-D2 (approx. 25%) and tachysterol 3 or tachysterol~ (approx.) 75%) are Eormed. This mixture is then irradiated with laser light in the wavelength range 330-360 nm. A nitrogen laser which functions at 337 nm or a YAG laser at 353 nm are suitable for this step. Other types of lasers that may also be used are XeF lasers at 350 nm, Raman shifted XeCl lasers, and broadband dye lasers pumped by ~eCl or KrF excimer lasers, the last two being tunable to operate as required in the 330-360 nm range. This second photolysis step produces a mixture that is approx. 95% pre-vitamin-D3 or pre-vitamin D2. The remaining 5% (approx.) is lumisterol or other isomers.
The pre-vitamin-D is then~converted to vitamin-D by thermolysis.
Figure 2 shows a suitable apparatus arrangement for carrying out the process and includes a reaction chamber 10 preferably of glass having a quartz end window 11 at one end. The starting -materials ei~her 7-DHC or ergosterol which are normally solid but which are dissolved in a suitable solvent e.g. di-ethyl ether are fed into port 12 and flow down chamber 10 and out port 13 to the second stage irradiation chamber 20. Light at the selected frequency from laser 14 passes through window 11 and irradiates the material flowing therein. The temperature of the material is held in the range 0-20C
by water jacket 15 enveloping chamber 10. This temperature is not critical. The second stage is similar to the first in that the material flowing through chamber 20 is irradiated by a laser beam in the appropriate frequency range from laser 24 passes through quartz window 21 into the flowing mixture. A water jacket 25 maintains the flowing material in the required temperature range. Products from the second stage pass to the thermolysis stage 28 which consists of heating the material to about 60C to convert the pre-vitamin d2 or -d3 to vitamin -d2 or -d3.
~8~7~
IE in stage l, a mercury arc lamp is used rather than a laser, then this can readily be achieved by lamp tube 16 helically surrounding chamber 10. In addition it might be convenient to carry out both stages of irradiation in a single chamber. This 5 is done by a second laser 17 at the appropriate Erequency irradiating the mixture through quart~ end window 18.
In the above description of ~he process the starting materials are 7-dehydro-cholesterol or ergosterol, The di-hydroxy form oE these materials may also be used as starting materials and 10 with the same process as outlined above will ~r~ee~ee the di-hydro~y version of the vitamin -D3 or vitamin -D2. It is therefore pointed out that wherein the terminology: 7-dehydro-cholesterol; ergosterol;
pre-vitamin-D2 or -D3; and vitamin -D2 or -D3 is used in this disclosure and claims that these terms include the di-hy.droxy form 15 of these materials.
The second stage of the two step irradiation process mentioned above may be readily applied to present methods that produce vitamin -D but with large percentages of tachysterol, lumisterol, or other isomers also produced. The photolysis step 20 us:Lng laser light in the 330-360nm range provides an efficient and economic method of upgrading the product produced by present methods and a,voids the need for derivativi~.ation and fractional re-crystalli-zation.
10 of cholesterol by ultraviolet light changes the compound and produces vitamin D.
The complex photochemistry of 7-dehydro-cholesterol (7-DHC) and ergosterol ~E) is now moderately well understood due to the studies of E. Havinga and his co-workers. See especially the following papers: Loevoet A.L.; Verloop A.; and Havinga E., Red. Trav.
Chim., Pays-Bas, 1955, 74,788 and Boosma F.; Jacobs H.J.C.; and Havinga E.; Vanclès Gen. ~., Tetrahedron Litt. 1975, 7,427.
The present commercial method of vitamin-D production involves a number of fractional crystallizations to isolate the required product. This method is described in French Patent No:
1,378,122, issued 1964 to K.R. Bhaurichter and F.M. Martin.
The use of photolysis with lasers or other light sources to achieve product separation is now well known. The use of photolysis in the production of vitamin-D is known but present methods have had the problem of the production of side products such as tachysterol, lumisterol and other isomers. These methods have required additional process steps such as fractional distillations to obtain the required separation percentages.
It is an object of the present invention to provide a method of producing vitamin-D that gives improved yields and reduced side product contamination.
This and other objects of the invention are achieved by a method involving photolysis at a selected wavelength.
In drawings which illustrate an embodiment of the 40 invention:
Figure 1 is a flow diagram of the process, and 67~
Figure 2 is a cross-sectio~al view of apparatus for carrying out the process.
Referring to figure 1~ the starting material, 7-dehydro-cholesterol (7-D~C) or ergosterol is irradiated with light in the wavelength range 245-260 mm. A low pressure mercury arc which functions at 254 nm. is most suitable for this. This photolysis may also be achieved by the use of an excimer laser ~KrF at 248 nm). Pre-vitamin-D3 or pre-vitamin-D2 (approx. 25%) and tachysterol 3 or tachysterol~ (approx.) 75%) are Eormed. This mixture is then irradiated with laser light in the wavelength range 330-360 nm. A nitrogen laser which functions at 337 nm or a YAG laser at 353 nm are suitable for this step. Other types of lasers that may also be used are XeF lasers at 350 nm, Raman shifted XeCl lasers, and broadband dye lasers pumped by ~eCl or KrF excimer lasers, the last two being tunable to operate as required in the 330-360 nm range. This second photolysis step produces a mixture that is approx. 95% pre-vitamin-D3 or pre-vitamin D2. The remaining 5% (approx.) is lumisterol or other isomers.
The pre-vitamin-D is then~converted to vitamin-D by thermolysis.
Figure 2 shows a suitable apparatus arrangement for carrying out the process and includes a reaction chamber 10 preferably of glass having a quartz end window 11 at one end. The starting -materials ei~her 7-DHC or ergosterol which are normally solid but which are dissolved in a suitable solvent e.g. di-ethyl ether are fed into port 12 and flow down chamber 10 and out port 13 to the second stage irradiation chamber 20. Light at the selected frequency from laser 14 passes through window 11 and irradiates the material flowing therein. The temperature of the material is held in the range 0-20C
by water jacket 15 enveloping chamber 10. This temperature is not critical. The second stage is similar to the first in that the material flowing through chamber 20 is irradiated by a laser beam in the appropriate frequency range from laser 24 passes through quartz window 21 into the flowing mixture. A water jacket 25 maintains the flowing material in the required temperature range. Products from the second stage pass to the thermolysis stage 28 which consists of heating the material to about 60C to convert the pre-vitamin d2 or -d3 to vitamin -d2 or -d3.
~8~7~
IE in stage l, a mercury arc lamp is used rather than a laser, then this can readily be achieved by lamp tube 16 helically surrounding chamber 10. In addition it might be convenient to carry out both stages of irradiation in a single chamber. This 5 is done by a second laser 17 at the appropriate Erequency irradiating the mixture through quart~ end window 18.
In the above description of ~he process the starting materials are 7-dehydro-cholesterol or ergosterol, The di-hydroxy form oE these materials may also be used as starting materials and 10 with the same process as outlined above will ~r~ee~ee the di-hydro~y version of the vitamin -D3 or vitamin -D2. It is therefore pointed out that wherein the terminology: 7-dehydro-cholesterol; ergosterol;
pre-vitamin-D2 or -D3; and vitamin -D2 or -D3 is used in this disclosure and claims that these terms include the di-hy.droxy form 15 of these materials.
The second stage of the two step irradiation process mentioned above may be readily applied to present methods that produce vitamin -D but with large percentages of tachysterol, lumisterol, or other isomers also produced. The photolysis step 20 us:Lng laser light in the 330-360nm range provides an efficient and economic method of upgrading the product produced by present methods and a,voids the need for derivativi~.ation and fractional re-crystalli-zation.
Claims (4)
1. A method of production of vitamin-D2 or vitamin-D3 using ergosterol or 7-dehydro-cholesterol or their dihydroxy derivatives as the starting materials, comprising:
a) irradiating the starting material with light in the wavelength range 245-260 nanometers to obtain a product containing pre-vitamin-D2 or pre-vitamin-D3 as a minor proportion and tachysterols as a major pro-portion, b) irradiating this product with light in the wavelength range 330-360 nanometers to obtain a product containing pre-vitamin-D2 or pre-vitamin-D3 as a major proportion, and c) heating this product to convert the pre-vitamin-D2 or pre-vi-tamin-D3 to vitamin-D2 or vitamin-D3, the intermediates and final pro-ducts being the dihydroxy derivatives when the starting material is in this form.
a) irradiating the starting material with light in the wavelength range 245-260 nanometers to obtain a product containing pre-vitamin-D2 or pre-vitamin-D3 as a minor proportion and tachysterols as a major pro-portion, b) irradiating this product with light in the wavelength range 330-360 nanometers to obtain a product containing pre-vitamin-D2 or pre-vitamin-D3 as a major proportion, and c) heating this product to convert the pre-vitamin-D2 or pre-vi-tamin-D3 to vitamin-D2 or vitamin-D3, the intermediates and final pro-ducts being the dihydroxy derivatives when the starting material is in this form.
2. A method of upgrading a product containing a minor proportion of pre-vitamin-D2 or pre-vitamin-D3 or their dihydroxy deri-vatives and a major proportion of tachysterols comprising:
a) irradiating the product with light in the wavelength range 330-360 nanometers to obtain a product containing pre-vitamin-D2 or pre-vitamin-D3 as a major proportion, and b) heating this product to convert the pre-vitamin-D2 or pre-vita-min-D3 to vitamin-D2 or vitamin-D3 , the intermediates and final products being the dihydroxy derivatives when the starting material is in this form.
a) irradiating the product with light in the wavelength range 330-360 nanometers to obtain a product containing pre-vitamin-D2 or pre-vitamin-D3 as a major proportion, and b) heating this product to convert the pre-vitamin-D2 or pre-vita-min-D3 to vitamin-D2 or vitamin-D3 , the intermediates and final products being the dihydroxy derivatives when the starting material is in this form.
3. A method of production of vitamin-D2 or vitamin-D3 u-sing ergosterol or 7-dehydro-cholesterol as the starting materials com-prising:
a) irradiating the starting material with light in the wavelength range 245-260 nanometers to obtain a product containing pre-vitamin-D2 or pre-vitamin-D3 as a minor proportion and tachysterol2 or tachyste-rol3 as a major proportion, b) irradiating this product with light in the wavelength range 330-360 nanometers to obtain a product containing approximately 95% pre-vitamin-D2 or pre-vitamin-D3, and c) heating this product to convert the pre-vitamin-D2 or pre-vitamin-D3 to vitamin D2 or vitamin D3.
a) irradiating the starting material with light in the wavelength range 245-260 nanometers to obtain a product containing pre-vitamin-D2 or pre-vitamin-D3 as a minor proportion and tachysterol2 or tachyste-rol3 as a major proportion, b) irradiating this product with light in the wavelength range 330-360 nanometers to obtain a product containing approximately 95% pre-vitamin-D2 or pre-vitamin-D3, and c) heating this product to convert the pre-vitamin-D2 or pre-vitamin-D3 to vitamin D2 or vitamin D3.
4. A method of upgrading a product containing a minor proportion of pre-vitamin D2 or pre-vitamin D3 and a major proportion of tachysterols comprising:
a) irradiating the product with light in the wavelength range 330-360 nanometers to obtain a product containing approximately 95%
pre-vitamin-D2 or pre-vitamin-D3, and b) heating this product to convert the pre-vitamin-D2 or pre-vitamin-D3 to vitamin-D2 or vitamin-D3.
a) irradiating the product with light in the wavelength range 330-360 nanometers to obtain a product containing approximately 95%
pre-vitamin-D2 or pre-vitamin-D3, and b) heating this product to convert the pre-vitamin-D2 or pre-vitamin-D3 to vitamin-D2 or vitamin-D3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000395862A CA1180679A (en) | 1982-02-09 | 1982-02-09 | Method of production of vitamin-d |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000395862A CA1180679A (en) | 1982-02-09 | 1982-02-09 | Method of production of vitamin-d |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1180679A true CA1180679A (en) | 1985-01-08 |
Family
ID=4122011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000395862A Expired CA1180679A (en) | 1982-02-09 | 1982-02-09 | Method of production of vitamin-d |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1180679A (en) |
-
1982
- 1982-02-09 CA CA000395862A patent/CA1180679A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4388242A (en) | Method of production of vitamin-D | |
| Migirdicyan et al. | Electron spectra of o-and m-xylylenes and their methylated derivatives. Experimental and theoretical study | |
| Yogev et al. | Photochemistry in the electronic ground state. Quantitative electrocyclic isomerization induced by multiphoton absorption of infrared laser radiation | |
| Banwell et al. | A chemoenzymatic synthesis of the linear triquinane (−)-hirsutene and identification of possible precursors to the naturally occurring (+)-enantiomer | |
| Morton et al. | The absorption spectrum of vitamin A | |
| Rajapaksa et al. | A stereocontrolled synthesis of antineoplastic Podophyllum lignans | |
| Wagner | Photoreduction of acetone by tributylstannane | |
| Huffman | Metal-ammonia reductions of cyclic aliphatic ketones | |
| Nebe et al. | Photolysis of cis, cis-1, 3-cyclooctadiene | |
| CA1180679A (en) | Method of production of vitamin-d | |
| Padwa et al. | Photochemical transformations of small ring carbonyl compounds. XX. Transannular hydrogen abstraction in small ring carbocyclic systems | |
| Wilson et al. | Laser photochemistry: The wavelength dependent oxidative photodegradation of vitamin K analogs | |
| JP4364529B2 (en) | Oxygen isotope enrichment method and apparatus | |
| Arai et al. | Practical separation of silicon isotopes by IRMPD of Si2F6 | |
| US4120767A (en) | Photochemical method for carbon isotopic enrichment | |
| Favaro et al. | Kinetic analysis of the photochromic behavior of a naturally occurring chromene (lapachenole) under steady irradiation | |
| Abruscato et al. | Tri-tert-butylethylene | |
| DE3308592C2 (en) | Photochemical Process for the Production of Previtamin D ↓ 2 ↓ and D? 3? from ergosterol or 7-dehydrocholesterol | |
| Caine et al. | Influence of substituents on the photochemical behavior of cross-conjugated cyclohexadienones. Facile total synthesis of (-)-cyclocolorenone | |
| Iwata et al. | A stereoselective total synthesis of (±)-oxylubimin | |
| Saltiel et al. | Conformer-specific photoconversion of 25-hydroxytachysterol to 25-hydroxyprevitamin D3: role in the production of vitamin Ds | |
| Demuth et al. | Novel Variant of the Tricyclooctanone Approach to Cyclopentanoid Natural Products. Synthesis of (±)‐Coriolin. Preliminary Communication | |
| Van Audenhove et al. | A (π2+ π2) photocycloaddition reaction as a facile route to angularly substituted cis-hydrindanes and cis-decalanes | |
| Goldschmidt et al. | Photochemistry of 2-methylene-6, 7-benzobicyclo [3.2. 2] nona-3, 6, 8-triene. Efficient triplet DI-π-methane rearrangement of a “free-rotor” polyene. | |
| Mizuno et al. | Photochemical reactions of aromatic compounds. Part XXIII. Photochemical reactions of alkyl vinyl ethers with 2-naphthonitrile |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |